MLYS

13.6803.39%
RM

Robert McKean

Senior Vice President of CMC

Dr. Robert McKean, also known as Rob, Ph.D., is Senior Vice President of CMC at Mineralys Therapeutics, Inc. He is experienced in branded drug pharmaceutical development including preformulation studies through technology transfer to commercial manufacturing organizations. He is Senior Vice President, Chemistry, Manufacturing and Control (CMC) at Mineralys Therapeutics, Inc. He manages drug substance and drug product production for lead drug candidates. Prior to Mineralys Therapeutics, Inc., Dr. McKean held the position of VP, CMC at Oncopia Therapeutics where he developed protein degraders for oncology and VP, CMC at Teva Branded Pharmaceuticals. Dr. McKean has extensive drug development experience for new chemical entities and GMP manufacturing of clinical dosage forms. His experience covers traditional solid and liquid dosage forms plus nanoparticle drug delivery, poorly soluble drug delivery and transdermal drug delivery. Dr. McKean contributed to 9+ new drug application (NDA) approvals and numerous IND/CTA submissions in the US and Europe. Prior to Teva/Cephalon, Dr. McKean held similar positions at Aventis, Rhone-Poulenc Rorer and Searle. He received a BS in Chemistry from the University of Hartford and a Ph.D. in Chemistry from the University of Massachusetts at Amherst. Dr. McKean has several patents and publications in the areas of drug crystallization, new drug physical and chemical characterization and new drug formulations.

Positions